- Contractors
- Synergene Therapeutics Inc
Synergene Therapeutics Inc
Federal contractor · Research and Development in Biotechnology (except Nanobiotechnology)
Synergene Therapeutics has 1 federal contract of $100,000 or more active since October 2023, with $7.59M obligated, from 1 agency. None is running now.
- Contracts
- 1 since FY2024$7,589,344 obligated, contracts of $100,000 or more
- Running now
- None
- Biggest customer
- Defense Threat Reduction Agency$7.59M on 1 contract
- Main industry
- Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714
- UEI
- W8E3G5851JK4Unique entity ID in SAM.gov
- Source
- USAspending.govUpdated Nov 17, 2026, 7:02 PM UTC
Running contracts
No contract of $100,000 or more is running now.
Who they work for
| Agency | Amount | Share |
|---|---|---|
| Defense Threat Reduction Agency1 contract | $7,589,344 |
What they sell
| Industry | Amount | Share |
|---|---|---|
| Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714 · 1 contract | $7,589,344 |
Where the work is
| Place of work | Amount | Share |
|---|---|---|
| Maryland1 contract | $7,589,344 |
Source: USAspending.gov, prime contracts of $100,000 or more with an action since October 1, 2023. Department of Defense contracts appear there about 90 days after award. Other contracts ending soon at Defense Threat Reduction Agency: see the list.
Get new notices like Synergene Therapeutics's work
New contract opportunities under NAICS 541714, research and development in biotechnology (except nanobiotechnology), the morning they appear. Free while in beta.
Free. We use your email only for these alerts and never share it. Privacy